Compare LEN & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEN | IQV |
|---|---|---|
| Founded | 1954 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0B | 36.4B |
| IPO Year | N/A | 2013 |
| Metric | LEN | IQV |
|---|---|---|
| Price | $118.63 | $221.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 17 |
| Target Price | $125.13 | ★ $237.59 |
| AVG Volume (30 Days) | ★ 10.1M | 1.3M |
| Earning Date | 12-16-2025 | 10-28-2025 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.16 | 7.30 |
| Revenue | ★ $34,766,213,000.00 | $15,904,000,000.00 |
| Revenue This Year | N/A | $6.14 |
| Revenue Next Year | $3.19 | $5.35 |
| P/E Ratio | ★ $11.75 | $30.43 |
| Revenue Growth | N/A | ★ 3.85 |
| 52 Week Low | $98.42 | $134.65 |
| 52 Week High | $157.45 | $234.30 |
| Indicator | LEN | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 50.89 |
| Support Level | $117.04 | $217.86 |
| Resistance Level | $122.79 | $230.80 |
| Average True Range (ATR) | 3.67 | 5.33 |
| MACD | -0.97 | -1.09 |
| Stochastic Oscillator | 12.05 | 39.49 |
Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.